{"prompt": "['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'IS AMENDED TO:', 'The family-wise type I error rate for this study is strongly controlled at 2.5% (one-sided)', 'that allows the study to declare positive on primary endpoint OS on the FAS population.', 'OS will be formally tested at both interim analysis and final analysis. At either interim or', 'final analysis, the formal hypothesis tests on the selected secondary endpoints including', 'PFS1, ORR and DCR, will be performed hierarchically (per the order of PFS1-> ORR-', '>DCR) only when the os analysis is rejected. PFS1 is planned to test at either the', 'interim analysis or final analysis when os is rejected. ORR and DCR will be tested', 'only once after both OS and PFS1 are rejected (at either interim analysis or final', 'analysis) and the test statistics will be computed from the interim data. DCR will be', 'tested after ORR is rejected. The details about the significance levels at interim analysis', 'and final analysis for each efficacy endpoints (OS, PFS1, ORR and DCR) is are specified', 'in SAP.', '7 Statistical Methodology', '7.4.2.1 Progression Free Survival', 'ADDED:', 'In addition, subjects who have PD or death after 2 or more missed disease', 'assessments will be censored at the last disease assessment prior to the 2 or more', 'missed disease assessments.', '7 Statistical Methodology', '7.4.2.3 Duration of Response', 'ADDED:', 'Subjects who receive any further anti-cancer therapy for the disease before', 'radiological progression will be censored at the date of the last radiological', 'assessment before the anticancer therapy started. In addition, subjects who have PD', 'or death after 2 or more missed disease assessments will be censored at the last', 'disease assessment prior to the 2 or more missed disease assessments.', '14 Sep 2020', 'Astellas', 'Page 141 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', '14', \"COORDINATING INVESTIGATOR'S SIGNATURE\", 'An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs', 'Chemotherapy in Subjects with Previously Treated Locally Advanced or', 'Metastatic Urothelial Cancer (EV-301)', 'ISN/Protocol 7465-CL-0301', 'Version 4.0 Incorporating Substantial Amendment 3', '14 Sep 2020', 'I have read all pages of this clinical study protocol for which Astellas is the sponsor. I agree that it', 'contains all the information required to conduct this study.', 'Coordinating Investigator:', 'Signature:', '<Insert name, department/afiliation, name of institution>', 'Date (DD MMM YYYY)', 'Printed Name:', 'Address:', '14 Sep 2020', 'Astellas', 'Page 142 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', '15', \"SPONSOR'S SIGNATURES\", '14 Sep 2020', 'Astellas', 'Page 143 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']\n\n###\n\n", "completion": "END"}